hUC-MSC for Erectile Dysfunction (ED)
Delivered via intracavernous injection, hUC-MSCs exert paracrine effects that promote angiogenesis, neurorestoration and antifibrotic remodeling within the corpus cavernosum, addressing the underlying vascular, neural and fibrotic tissue damage that contributes to erectile dysfunction.
Clinical challenge
PDE5 inhibitors are common first-line therapy, but they are symptom-oriented and may be unsuitable for patients using nitrate medications.
Device therapy, intracavernosal medication injection, or surgery can create practical burden, variable acceptance, and higher perceived treatment friction.
Patients with diabetes, vascular risk factors, or nerve injury may require deeper specialist assessment before a regenerative pathway is considered.
Regenerative rationale
Local hUC-MSC delivery is reviewed for paracrine effects that may support angiogenesis, neurorestoration, and smooth-muscle microenvironment repair.
The pathway is framed around cavernous tissue remodeling, antifibrotic signaling, and recovery of endothelial and neural function.
Clinical discussion should remain eligibility-based, with outcomes assessed through specialist review rather than generalized promises.
Pre-review materials
IIEF-5 or EHS scoring, ED duration, prior PDE5 inhibitor response, and current medication list
Metabolic and vascular risk review, including diabetes status, blood pressure, lipid profile, testosterone when relevant, and PSA screening
Specialist tests may include nocturnal erection monitoring, penile Doppler ultrasound, and broader urology evaluation
